Maravai LifeSciences Holdings, Inc. Q3 FY2025 earnings call

New management team stabilized operations, reduced expenses by over $50 million annualized. BST's sickness business has 100% coverage in biologics space, expanding HCP assay portfolio. NAP's discovery consumables showed growth, ModTail technology and IVT kits launched, and CDMO services have strong funnel. Focus on operational excellence, revenue growth, and return to positive adjusted EBITDA in 2026.

For Q3 2025, total revenue was $41.6 million. Biologic Safety Testing (BST) generated $16.3 million, growing 7% year-over-year, contributing 39% of total revenue. Nucleic Acid Products (NAP) contributed $25.4 million, declining 53% year-over-year, making up 61% of total revenue. BST's adjusted EBITDA was $10.5 million with a 64.8% margin. NAP's base business (excluding COVID GMP CleanCap) was down 29% year-over-year, but discovery consumables saw Q3-Q2 growth and GMP consumables expect strong Q4 growth.

Anticipate 2025 revenue ~$185 million, Q4 growth 18% over Q3 (excluding COVID GMP CleanCap, Q4 base business growth 16% YOY). 2025 adjusted EBITDA loss ~$35 million, Q4 adjusted EBITDA loss ~$3.5 million. Target for positive adjusted EBITDA and cash flow in 2026 remains intact.

Dependence on lumpy order timing in GMP/CDMO, macro/funding challenges affecting Discovery, China market weakness impacting BST, and temporary BST EBITDA margin reduction due to labor/overhead methodology changes.

Q: Anticipated $10 million to $20 million revenue contribution from CleanCap in 2026?

A: Bernd Brust stated it's a combination of orders in hand and customer discussions.

Q: Cost savings split between COGS and SG&A?

A: Rajesh Asarpota said roughly 50-50, with 40-50% from labor, 15-20% from facilities, CapEx, and other controllable spend.

Q: BST regional strength?

A: Bernd Brust mentioned strength in US and Europe, with China still weak but funding improving.

Q: Long-term normalized growth rate for NAP?

A: Bernd Brust said difficult to quantify, but mRNA therapeutics offer upside depending on clinical trial progress.

Q: Confidence in ex-COVID GMP CleanCap in 4Q and 2026?

A: Bernd Brust and Rajesh Asarpota stated high confidence in Q4 with orders in hand, strong visibility for 2026 with more orders than 2024.